期刊文献+

急性病毒性脑炎血D-二聚体水平变化意义 被引量:3

Clinical Significance of D-dimer Levels in Children with Acute Virus Encephalitis
下载PDF
导出
摘要 目的 观察D -二聚体在血中含量变化 ,了解急性病毒性脑炎发病过程中凝血功能变化及临床意义。方法 选择 2 8例急性病毒性脑炎患儿为研究对象 ,分别于急性期和恢复期采清晨空腹静脉血 ,用ELISA测D -二聚体含量 ,并与 2 8例健康儿童对照。结果 急性病毒性脑炎D -二聚体含量急性期为 (0 4 16± 0 15 6 )mg/L ,恢复期为 (0 2 0 8± 0 10 2 )mg/L ,二者比较 P <0 .0 1,差别有显著性 ;对照组为 (0 182± 0 0 92 )mg/L ,与急性期比较P <0 .0 1,差异有极显著性 ;恢复期与对照组比较P >0 .0 5 ,差异无显著性。结论 病毒性脑炎急性期存在高凝状态 ,D -二聚体水平对高凝状态的检测及治疗有重要意义。 Objective To explore the content changes of D-dimer in blood,investigate the clinical significance of blood coagulant function in the process of acute virus encephalitis.Methods 28 children with acute virus encephalitis were selected,venous blood specimens were taken with empty stomach in the morning.The contents of D-dimer was determined with ELISA,28 health children as control.Results The level of D-dimer in patients during acute period was 0.146±0.156mg/L,in recovery was 0.208±0.102mg/L(vs acute stage, P< 0.01 ).The level of D-dimer in control was 0.182±0.092mg/L(VS acute stage,P< 0.01 ).In recovery and control,two groups were about the same ,P>0.05.Conclusion Hypercoaguliability was in the acute period of virus encephalitis.D-dimer might play a role in detection or therapy with the hypercoaguliability condition.
作者 王峰 刘成军
出处 《医药论坛杂志》 2004年第10期31-32,共2页 Journal of Medical Forum
关键词 急性病毒性脑炎 血液 D-二聚体 小儿 检测 Virus Eucephalitis Children D-dimer
  • 相关文献

参考文献2

二级参考文献3

  • 1程德云.血小板激活因子检测方法进展[J].国外医学(临床生物化学与检验学分册),1994,15(5):212-214. 被引量:4
  • 2吴瑞萍 胡亚美 江载芳.诸福堂[A]..实用儿科学:第6版[C].北京:人民卫生出版社,1996.753-753.
  • 3许积德.小儿内科学[M]:第3版[M].北京:人民卫生出版社,1997.338-338.

共引文献12

同被引文献18

  • 1吴保敏,王华,叶露梅,孙若鹏,秦炯,刘智胜,申昆玲,钱渊,邹丽萍,杨锡强,周水珍,王立文,麦坚凝,吴家骅.小儿病毒性脑炎的诊断与治疗[J].中国实用儿科杂志,2004,19(7):385-402. 被引量:131
  • 2黄波,伍爱平,陈冬妹,刘勇,李政,高添喜,黄惠伦.颅脑损伤血浆D-二聚体含量与伤情严重程度及预后的关系[J].中国误诊学杂志,2004,4(7):992-993. 被引量:10
  • 3Gueguen G,Gaige,Grevy JM,et al.Structure activity analysis of the effects of lysophosphatidic acid on platelet aggregation[J].Biochemistry,1999,38 (26):8440-8450.
  • 4许积德.小儿内科学[M].3版,北京:人民卫生出版社,1997.338.
  • 5Thomas M,Mc Intyre,Aaron V,et al.Identification of an intracellular receptor for lysophosphatidic acid (LPA):LPA is a transcellular PPAR vagonist[J].Proc Natl Acad Sci USA,2003,100:7-10.
  • 6Baker RR,Chang H.A metabolic path for the degradation of lysophosphatidic acid,an inhibitor of lysophosphatidyl choline lysophospholipase,in neuronal nuclei of cerebral cortex[J].Biochem Biophys Acta,2000,1483:58-68.
  • 7Pages C,Simon MF,Valet P,et al.Lysophosphatidic acid synthesis and release[J].Prosta Glandins Other Lipid Mediat,2001,64:1-10.
  • 8Soto W,Takahashi H,Shibate A.Fibrinogen/Fibrin degradation Products and D-dimer in Clinical Practice:interpretation of discrepant results[J].Am J Hematol,1995,48(3):168-174
  • 9Seewant DJ, Levy RD, Ceracek Pet al. Increased plasma EP - 1 in pulmonary hypertention: marker or mediator of disease. Aun Intern Med, 1991, 114 (6): 464
  • 10Bone RC. Sirisaaenewtow: sepsis, SIRS, andCARS. Crit Care Med, 1996, 24 (7): 1125

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部